Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 2/20 | 0.30 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8301690 | 1.00 | TRPA1 (0.38) | TRPA1POLBEPHX2EPHX1MEN1 | |
| SCHEMBL2019181 | 0.76 | CTSK (0.33) | CTSK | |
| SCHEMBL13051375 | 0.76 | CTSK (0.33) | EPHX1ALOX15CTSK | |
| SCHEMBL24441870 | 0.75 | CYP2C9 (0.42) | MEN1KMT2ACTSK | |
| SCHEMBL14612334 | 0.74 | CTSK (0.32) | CTSK | |
| SCHEMBL15338780 | 0.73 | CTSK (0.33) | MEN1KMT2ARAB9ACTSK | |
| SCHEMBL7945239 | 0.72 | CTSK (0.38) | CTSK | |
| SCHEMBL23917859 | 0.72 | CTSK (0.32) | CTSK | |
| SCHEMBL24567754 | 0.71 | POLB (0.45) | TRPA1POLBEPHX2EPHX1MEN1 | |
| SCHEMBL18793674 | 0.71 | POLB (0.45) | TRPA1POLBEPHX2EPHX1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431733-B2 | Process for the preparation of (3S)-3-amino-N-cyclopropyl-2-hydroxyalkanamide derivatives | VIROBAY, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8143448-B2 | Process for the preparation of (3S)-3-amino-N-cyclopropyl-2-hydroxyalkanamide derivatives | VIROBAY, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20090312571-A1 | PROCESS FOR THE PREPARATION OF (3S)-3-AMINO-N-CYCLOPROPYL-2-HYDROXYALKANAMIDE DERIVATIVES | VIROBAY, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| WO-2009152200-A1 | TRICYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2009-12-17 | — | — | WO | disclosed |
| US-20090234127-A1 | PROCESS FOR THE PREPARATION OF (3S)-3-AMINO-N-CYCLOPROPYL-2-HYDROXYALKANAMIDE DERIVATIVES | VIROBAY, INC. (US) | 2009-09-17 | — | — | US | disclosed |
| US-20080045530-A1 | Organic Compounds and Their Uses | BRANDL TRIXI | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090234127-A1 | PROCESS FOR THE PREPARATION OF (3S)-3-AMINO-N-CYCLOPROPYL-2-HYDROXYALKANAMIDE DERIVATIVES | CTSS, CTSV, CTSE | TRPA1 3131/4885POLB 1664/4885EPHX2 1846/4885 |
| US-20080045530-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | TRPA1 748/4885POLB 419/4885EPHX2 1389/4885 |
| US-20090312571-A1 | PROCESS FOR THE PREPARATION OF (3S)-3-AMINO-N-CYCLOPROPYL-2-HYDROXYALKANAMIDE DERIVATIVES | HCN3, NPEPPS, HACL2 | TRPA1 2097/4885POLB 1745/4885EPHX2 1299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.